Evofem Biosciences Inc (NASDAQ:EVFM) noted an increase of 42.5% in shares shorted. FINRA issued in April EVFM’s total 189,100 shares shorted. The up change of 42.5% from 132,700 shares was reported. Evofem Biosciences Inc (NASDAQ:EVFM) has 11,200 shares average volume. It’ll cost 17 days for EVFM to recover its former position. Evofem Biosciences Inc float short is 0.75%.

The stock decreased 1.15% or $0.04 during the last trading session, hitting $3.43.Currently Evofem Biosciences, Inc. is downtrending after 55.18% change in last April 6, 2018. EVFM has also 748 shares volume. EVFM underperformed the S&P 500 by 59.55%.

Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products.The firm is valued at $96.58 million. The Company’s lead product candidate is Amphora that is in Phase 3 trial for contraception; and in Phase 2b/3 clinical trial for prevention of chlamydia and gonorrhea in women.Currently it has negative earnings. The firm is also developing vaginal gel product candidate for the treatment of recurrent bacterial vaginosis.

For more Evofem Biosciences, Inc. (NASDAQ:EVFM) news published briefly go to: Prnewswire.com, Benzinga.com, Nasdaq.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Evofem Biosciences to Present at Needham Healthcare Conference – PRNewswire” published on April 03, 2019, “20 Stocks Moving In Monday’s Pre-Market Session – Benzinga” on December 17, 2018, “Health Care Sector Update for 12/17/2018: PTI, EVFM, BCLI, JNJ, PFE, MRK, ABT, AMGN – Nasdaq” with a publish date: December 17, 2018, “Evofem Biosciences, Inc. (EVFM) CEO Saundra Pelletier on Q3 2018 Results – Earnings Call Transcript – Seeking Alpha” and the last “Evofem Biosciences +2% on Q4 results – Seeking Alpha” with publication date: March 01, 2019.